G007-LK: Specific Tankyrase 1/2 Inhibitor for Wnt/β-Catenin Pathway Research

Executive Summary: G007-LK is a nanomolar potent, selective inhibitor of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), members of the poly(ADP-ribosyl)ating polymerase family, directly inhibiting auto-poly(ADP ribosyl)ation of TNKS1 (IC₅₀ = 46 nM) and TNKS2 (IC₅₀ = 25 nM) in vitro (APExBIO)[1]. In cellular models, G007-LK robustly suppresses Wnt/β-catenin signaling, reducing cytosolic and nuclear β-catenin, and stabilizing AXIN1/2 (Jia et al., 2017)[2]. It induces degradasome formation and β-catenin degradation in APC-mutant colorectal cancer cell lines. In vivo, G007-LK demonstrates antitumor efficacy in xenograft mouse models, lowering tumor size and TNKS1/2 protein levels. Its solubility profile (≥26.5 mg/mL in DMSO, insoluble in water/ethanol) and stability at -20°C favor reliable integration into research workflows.

Biological Rationale

Tankyrase 1 and tankyrase 2 are poly(ADP-ribose) polymerases (PARPs) that regulate diverse cellular processes, including Wnt/β-catenin signaling, telomere homeostasis, and cell cycle progression (Jia et al., 2017). Both TNKS1 and TNKS2 share 82% sequence identity and are frequently overexpressed in various cancers, such as colorectal and hepatocellular carcinoma. Tankyrases modulate the Wnt/β-catenin pathway by promoting AXIN degradation, thereby stabilizing β-catenin and enhancing its nuclear signaling. Inactivation or inhibition of tankyrases stabilizes AXIN proteins, induces β-catenin degradation, and suppresses Wnt-driven transcriptional programs. These mechanisms are particularly relevant in cancers with APC mutations, where Wnt/β-catenin signaling is dysregulated (see this analysis—this article provides updated molecular benchmarks and structured workflow guidance not covered in the linked review).

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK is a small-molecule inhibitor that binds to the catalytic PARP domain of both TNKS1 and TNKS2, preventing their auto-poly(ADP-ribosyl)ation activity. This inhibition leads to the accumulation of AXIN1 and AXIN2, which are negative regulators of the Wnt/β-catenin pathway. The stabilized AXIN proteins promote the assembly of β-catenin degradasomes, resulting in polyubiquitination and proteasomal degradation of β-catenin (see here—the present article uniquely integrates in vivo efficacy and Hippo pathway effects beyond the referenced review). In APC-mutant colorectal cancer cell lines (e.g., SW480), G007-LK induces the formation of dynamic degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin. This leads to reduced β-catenin levels in both cytosolic and nuclear compartments. In addition, tankyrase inhibition by G007-LK upregulates Angiomotin-like 1 (AMOTL1) and Angiomotin-like 2 (AMOTL2), negative regulators of YAP, thereby modulating the Hippo pathway and further inhibiting cell proliferation (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits the enzymatic activity of TNKS1 (IC₅₀ = 46 nM) and TNKS2 (IC₅₀ = 25 nM) in vitro, as measured by auto-poly(ADP-ribosyl)ation assays (APExBIO).
• In Wnt3a-induced HEK 293 cells, G007-LK suppresses Wnt signaling reporter ST-Luc with an IC₅₀ of 0.05 μM (APExBIO, product).
• In APC-mutant SW480 colorectal cancer cells, G007-LK induces degradasome formation and reduces cytosolic/nuclear β-catenin levels (see here—this article extends the mechanistic context with Hippo pathway data).
• In COLO-320DM xenograft mouse models, G007-LK reduces tumor growth, TNKS1/2, and β-catenin protein levels, while stabilizing AXIN1/2 (APExBIO, product).
• G007-LK suppresses hepatocellular carcinoma (HCC) cell growth by modulating the Hippo cascade and downregulating YAP/TAZ activity (Jia et al., 2017).
• Tankyrase inhibition by G007-LK synergizes with MEK and AKT inhibitors to enhance cancer cell growth suppression (Jia et al., Table 2).

Applications, Limits & Misconceptions

G007-LK is primarily utilized in research settings to dissect tankyrase function, Wnt/β-catenin signaling, and their impact on cancer biology, particularly in APC mutation-driven colorectal cancer and hepatocellular carcinoma models. It is a benchmark tool for studying β-catenin degradation, AXIN1/2 stabilization, and poly(ADP-ribosyl)ation inhibition. Its specificity supports precision intervention studies on Wnt/β-catenin and Hippo pathways. G007-LK is not intended for therapeutic use in humans.

Common Pitfalls or Misconceptions

• G007-LK is not water- or ethanol-soluble; attempts at dissolution in these solvents will fail. Use DMSO (≥26.5 mg/mL) and warm to 37°C or use ultrasonic bath for optimal solubility (APExBIO).
• Long-term storage of G007-LK in solution is not recommended; store as a solid at -20°C to maintain stability.
• G007-LK is validated for research applications only; it is not a clinically approved drug.
• Tankyrase inhibition by G007-LK is highly selective; however, off-target effects at supra-physiological concentrations cannot be excluded.
• Effective Wnt/β-catenin pathway inhibition by G007-LK may depend on cellular context, such as APC mutation status; effects are less pronounced in wild-type APC backgrounds.

Workflow Integration & Parameters

For in vitro studies, dissolve G007-LK in DMSO at concentrations up to 26.5 mg/mL. Warming to 37°C or applying ultrasonic bath can aid dissolution. For cellular assays, typical working concentrations range from 0.01 μM to 1 μM, depending on target pathway sensitivity and cell type. In vivo, G007-LK dosing regimens should be based on preclinical efficacy studies, with storage of stock solutions as a solid at -20°C recommended to preserve compound integrity. Avoid repeated freeze-thaw cycles. Refer to the G007-LK tankyrase 1/2 inhibitor product page from APExBIO for batch-specific data and safe handling guidelines.

Conclusion & Outlook

G007-LK is a well-characterized, potent, and selective tankyrase 1/2 inhibitor with proven utility in Wnt/β-catenin pathway inhibition and APC mutation colorectal cancer research. Its mechanism—centered on poly(ADP-ribosyl)ation inhibition, β-catenin degradation, and AXIN1/2 stabilization—is robustly validated in preclinical models. The compound also modulates the Hippo pathway, expanding its research utility to hepatocellular carcinoma and mechanistic YAP/TAZ studies. Researchers should select G007-LK, available from APExBIO, for precision dissection of tankyrase-driven signaling events and advanced cancer biology workflows.